Experience

EnzyQuest

• Greece
• Biotechnology Research
• 1 - 100 Employee

• Chief Executive Officer

  • Jan 2020 - Present



University of Crete

• Greece
• Higher Education
• 700 & Above Employee

• • 2009 - Present

  CoursesPostgraduate programme in Protein Biotechnology:-Enzyme Directed Evolution.-Heterologous Protein Expression SystemsUndergraduate programme in Biology:-Enzyme Biotechnology (laboratory course)

• • Feb 2009 - Sep 2015

  Identification of cell wall modifying enzymes of human pathogens as novel drug targets.Evaluation of chemical compounds as inhibitors of Bacillus anthracis cell wall modifying enzymes.



Global StartupCities initiative

• Spain
• Non-profit Organizations
• 1 - 100 Employee

• Innovation Team - StartupCity Heraklion at Global StartupCities initiative

  • Nov 2020 - Present



MINOTECH biotechnology

• MINOTECH biotechnology IMBB-FORTH Nikolaou Plastira 100 GR-70013 Heraklion GR

• Executive Director

  • Nov 2015 - Jan 2020

  My responsibilities include commercial organization, R&D activities and strategic partnerships with companies or academic institutions. My responsibilities include commercial organization, R&D activities and strategic partnerships with companies or academic institutions.



New England Biolabs

• United States
• Biotechnology Research
• 500 - 600 Employee

• Postdoctoral Researcher

  • 2006 - 2008

  Protein engineering on psychrophilic Alkaline Phospatase (AP).Mutant proteins were discovered with high potential of biotechnological applications. Identification of novel O-glycosidases. A protein family was discovered with a broader substrate specificity. This study resulted in a patent (WO 2009/129086 A2) and a new product by New England Biolabs Inc. (O-Glycosidase). Protein engineering on psychrophilic Alkaline Phospatase (AP).Mutant proteins were discovered with high potential of biotechnological applications. Identification of novel O-glycosidases. A protein family was discovered with a broader substrate specificity. This study resulted in a patent (WO 2009/129086 A2) and a new product by New England Biolabs Inc. (O-Glycosidase).